- Home
- PMM vs FDMT Comparison
PMM vs FDMT Comparison
Compare PMM & FDMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PMM | FDMT |
|---|---|---|
| Founded | 1989 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 262.2M | 391.8M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | PMM | FDMT |
|---|---|---|
| Price | $6.12 | $10.99 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $30.33 |
| AVG Volume (30 Days) | 118.3K | ★ 737.9K |
| Earning Date | 01-01-0001 | 11-10-2025 |
| Dividend Yield | ★ 4.68% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.23 | N/A |
| Revenue | N/A | ★ $120,000.00 |
| Revenue This Year | N/A | $21,181.08 |
| Revenue Next Year | N/A | $162.43 |
| P/E Ratio | $26.52 | ★ N/A |
| Revenue Growth | N/A | ★ 605.88 |
| 52 Week Low | $5.00 | $2.24 |
| 52 Week High | $6.42 | $12.34 |
Technical Indicators
Market Signals| Indicator | PMM | FDMT |
|---|---|---|
| Relative Strength Index (RSI) | 48.97 | 53.25 |
| Support Level | $6.07 | $10.30 |
| Resistance Level | $6.20 | $11.50 |
| Average True Range (ATR) | 0.08 | 0.70 |
| MACD | -0.00 | -0.02 |
| Stochastic Oscillator | 29.41 | 56.85 |
Price Performance
Historical ComparisonAbout PMM Putnam Managed Municipal Income Trust
Putnam Managed Municipal Income Trust is a closed-end management investment company. Its investment objective is to seek a high level of current income exempt from federal income tax by investing in a diversified portfolio of tax-exempt municipal securities. The Fund invests in various sectors such as healthcare, retirement community, private higher education, housing-backed, essential service utilities, and state-backed bonds.
About FDMT 4D Molecular Therapeutics Inc.
4D Molecular Therapeutics Inc is a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-125, 4D-110, and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector) 4D-310.